• Maridomycin: In Vitro and In Vivo Antibacterial Activity

  2026-08-13

  Kondo and colleagues characterized maridomycin through a combined analysis of antibacterial spectrum, environmental effects, resistance development, serum binding, bactericidal behavior, and efficacy in infected mice. The study’s main contribution was an integrated preclinical profile showing strong activity against Gram-positive organisms, selected Gram-negative pathogens, and experimental Gram-positive infections, while also revealing macrolide-associated cross-resistance and predominantly bacteriostatic behavior.

• Intravenous Cefazedone in Community-Acquired Pneumonia

  2026-08-12

  The reference study linked cefazedone exposure to microbiological susceptibility and the time that free drug concentrations remained above the MIC in patients with mild to moderate community-acquired pneumonia. Its small, open-label PK/PD design supports the rationality of 2 g every 12 hours while also clarifying the limits of extrapolating these findings beyond susceptible pathogens and uncomplicated clinical populations.

• Methicillin Sodium Salt for MSSA Research

  2026-08-12

  Methicillin sodium salt provides a practical benchmark for MSSA susceptibility testing, bacterial cell wall studies, and genotype–phenotype comparisons. Its predictable contrast with mecA-positive MRSA makes it especially useful for troubleshooting resistance assays and building strain-aware gram-positive infection models.

• Cy5-UTP RNA Labeling: Workflow & Troubleshooting

  2026-08-11

  Cy5-UTP enables direct, red-channel visualization of RNA generated by T7 in vitro transcription, supporting FISH, RNA probe synthesis, and dual-color expression arrays. This guide connects practical labeling choices with MALAT1–TDP-43 research and provides actionable optimization steps for signal, transcript quality, and assay reproducibility.

• Imipenem P10075 for Reproducible Cell Assays

  2026-08-10

  Learn how Imipenem (SKU P10075) can support controlled antibacterial research, immune response modulation, and cell-based assay workflows. This scenario-driven guide covers formulation compatibility, dose interpretation, resistance context, and practical vendor-selection criteria.

• CUDC-907: Dual PI3K and HDAC Workflow Guide

  2026-08-09

  CUDC-907 provides a research tool for coordinated interrogation of PI3K and histone deacetylase signaling in cancer cell models. This guide separates product-dossier specifications from workflow recommendations and is intended for controlled in vitro research, not diagnostic, therapeutic, or clinical use.

• IDO1 Inhibition and Tumor-intrinsic STAT3 Activation

  2026-08-08

  This study shows that pharmacological inhibition of IDO1 can produce a context-dependent, tumor-protective response: immune cells become more active, yet IL-6 released by infiltrating myeloid cells activates JAK2/STAT3 signaling inside tumor cells. Its single-cell analysis provides a mechanistic explanation for why IDO1 inhibition may require combination strategies that also block cytokine-driven tumor survival.

• PF-573228 FAK Inhibitor: Mechanotransduction Workflow

  2026-08-07

  PF-573228 provides a practical way to perturb FAK signaling in cancer migration, endothelial angiogenesis, and stiffness-responsive dentinogenesis assays. This workflow combines dose-aware treatment, phosphorylation readouts, matrix controls, and troubleshooting guidance to distinguish pathway inhibition from nonspecific toxicity.

• Gepotidacin for Uncomplicated Gonorrhea: Phase 2 Efficacy In

  2026-08-07

  This article reviews a pivotal phase 2 clinical study evaluating gepotidacin, a novel bacterial topoisomerase inhibitor, for the treatment of uncomplicated urogenital gonorrhea. The research demonstrates high single-dose efficacy and highlights the urgent need for alternative antibiotics amid rising resistance in Neisseria gonorrhoeae.

• DNase I (RNase-free): Enabling Precision in Translational Ge

  2026-08-06

  This article explores how DNase I (RNase-free) drives assay reproducibility and mechanistic insight in advanced RNA workflows. Blending evidence-based mechanistic guidance with real-world protocol advice, we examine the enzyme's role in translational research, highlight lessons from annexin V structural studies, and chart a strategic path for next-generation experimental design. Key differentiators include deep mechanistic rationales, a focus on chromatin and hybrid digestion, and actionable guidance for achieving DNA-free RNA in complex biological samples.

• 2'3'-cGAMP (sodium salt): Advancing STING Pathway Assays

  2026-08-06

  2'3'-cGAMP (sodium salt) unlocks sensitive, reproducible activation of the cGAS-STING axis for immunology, cancer, and antiviral research. This guide translates new mechanistic insights from hepatic injury models into actionable workflows and troubleshooting for precise innate immune modulation.

• HR-LCMS/MS Reveals Astragalus dasyanthus as a Source of Glab

  2026-08-05

  This study introduces a streamlined HR-LCMS/MS-based dereplication protocol to rapidly identify autophagy-inducing compounds in plant extracts, demonstrating its effectiveness by discovering Astragalus dasyanthus as a novel producer of glabrol. These findings enable more efficient high-throughput screening of natural autophagy inducers relevant to mitochondrial and metabolic research.

• Etoposide (VP-16): Data-Driven Solutions for Robust DNA Dama

  2026-08-05

  This article addresses persistent laboratory challenges in apoptosis induction and DNA damage assays, guiding biomedical researchers on how 'Etoposide (VP-16)' (SKU A1971) delivers reproducible, data-backed solutions. With real-world scenario Q&As and protocol insights, it demonstrates why this APExBIO-supplied topoisomerase II inhibitor remains a cornerstone for cancer cell research.

• Cefazedone (Refosporen): Mechanism, Efficacy, and Protocols

  2026-08-04

  Cefazedone (Refosporen) is a first-generation cephalosporin antibiotic with robust β-lactamase-resistant activity against both Gram-positive and Gram-negative bacteria. Its primary mode of action is the inhibition of bacterial cell wall synthesis, and it demonstrates consistent efficacy in established in vitro and in vivo protocols. This article details its biological rationale, mechanism, clinical benchmarks, and workflow integration for antibacterial testing.

• NPT1-Mediated Renal Transport of Faropenem Sodium and PAH: M

  2026-08-04

  This study provides the first molecular evidence that human NPT1, an apical membrane transporter in renal proximal tubules, mediates the transport of p-aminohippuric acid (PAH) and several organic anions, including faropenem. Through expression in HEK293 cells, the research clarifies NPT1's substrate profile and advances understanding of organic anion secretion, with implications for antibiotic disposition and pharmacokinetic modeling.

448 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page